Bioretec signed a U.S. distribution agreement with Spartan Medical covering RemeOs screws, manufactured from a proprietary biodegradable metal alloy, which received FDA 510(k) market clearance in early 2023. The signed distribution agreement signals the commencement of the rollout of RemeOs screws in the United States.
The agreement outlines the initiation of a controlled launch of the U.S. distribution of the RemeOsTM screws within strategically selected top-tier academic centers.
Additionally, the distribution agreement involves a potential to penetrate into the extensive U.S. Department of Defense and the Veterans Administration healthcare market.
Bioretec’s commercialization strategy for RemeOs screws also includes the involvement of local key opinion leaders, active participation of the company’s Scientific Advisory Board, and the use of comprehensive education and training platforms within selected academic centers. With this strategic approach, the goal is to engage the surgeon communities and gather postmarket data for the expansion of the RemeOs product portfolio and to raise awareness about the clinical benefits of RemeOs screws.
Bioretec signed a U.S. distribution agreement with Spartan Medical covering RemeOs screws, manufactured from a proprietary biodegradable metal alloy, which received FDA 510(k) market clearance in early 2023. The signed distribution agreement signals the commencement of the rollout of RemeOs screws in the United States.
The agreement...
Bioretec signed a U.S. distribution agreement with Spartan Medical covering RemeOs screws, manufactured from a proprietary biodegradable metal alloy, which received FDA 510(k) market clearance in early 2023. The signed distribution agreement signals the commencement of the rollout of RemeOs screws in the United States.
The agreement outlines the initiation of a controlled launch of the U.S. distribution of the RemeOsTM screws within strategically selected top-tier academic centers.
Additionally, the distribution agreement involves a potential to penetrate into the extensive U.S. Department of Defense and the Veterans Administration healthcare market.
Bioretec’s commercialization strategy for RemeOs screws also includes the involvement of local key opinion leaders, active participation of the company’s Scientific Advisory Board, and the use of comprehensive education and training platforms within selected academic centers. With this strategic approach, the goal is to engage the surgeon communities and gather postmarket data for the expansion of the RemeOs product portfolio and to raise awareness about the clinical benefits of RemeOs screws.
Copy to clipboard 
